LD-2 disclosure · 3rd Quarter - Report
ALKERMES, INC.
via ALKERMES, INC.
Client
- Name
- ALKERMES, INC.
- Location
- Massachusetts · United States of America
Registrant
- Firm
- ALKERMES, INC.
- Description
- Biopharmaceutical company
- Location
- Waltham, Massachusetts, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
Maintain six protected classes for depressions and schizophrenia under Medicare Part D; S. 2327 - Seniors Prescription Drug Relief Act H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 - Lower Costs, More Cures Act H.R.5260 - Reduced Costs and Continued Cures Act
LobbyistsPETER NORMAN · MEGAN JACKSON · mr ZACHARY MICHAEL MARSHALL
Covered position (mr ZACHARY MICHAEL MARSHALL): U.S. House of Representatives: Rep. Jim Cooper (2008-2014), Rep. John Yarmuth (2014-2019)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Office of Natl Drug Control Policy (NDCP) · Health & Human Services, Dept of (HHS) · Justice, Dept of (DOJ) · Veterans Affairs, Dept of (VA) · Natl Institutes of Health (NIH) · Substance Abuse & Mental Health Services Administration (SAMHSA)
Health Issues
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment;
LobbyistsPETER NORMAN · MEGAN JACKSON · WILLIAM PATRICK HIBBS · mr ZACHARY MICHAEL MARSHALL
Covered position (WILLIAM PATRICK HIBBS): U.S. House of Representatives: Rep. Ryan Costello (2015-2018)
Covered position (mr ZACHARY MICHAEL MARSHALL): U.S. House of Representatives: Rep. Jim Cooper (2008-2014), Rep. John Yarmuth (2014-2019)
